ID   LAMA84-rn
AC   CVCL_DP54
DR   Wikidata; Q54901918
RX   PubMed=19047160;
CC   Selected for resistance to: ChEBI; CHEBI_52172; Nilotinib (AMN107; Tasigna).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0388 ! LAMA-84
SX   Female
AG   29Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 13
//
RX   PubMed=19047160; DOI=10.1158/0008-5472.CAN-08-1008;
RA   Mahon, Francois-Xavier
RA   Hayette, Sandrine
RA   Lagarde, Valerie
RA   Belloc, Francis
RA   Turcq, Beatrice
RA   Nicolini, Franck
RA   Belanger, Coralie
RA   Manley, Paul W.
RA   Leroy, Cedric
RA   Etienne, Gabriel
RA   Roche, Serge
RA   Pasquet, Jean-Max
RT   "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or
RT   Src kinase overexpression.";
RL   Cancer Res. 68:9809-9816(2008).
//